FibroBiologics, Inc.
FBLG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001958777
No open-market purchases or sales by FibroBiologics, Inc. insiders were filed in the last 90 days; 16 institutions reported holding it in 13F filings for Q2 2026, worth $269.6K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by FibroBiologics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for FibroBiologics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Khoja Hamid | Chief Scientific Officer | 301,571 | Sep 15, 2026 | 3 |
| Hoffman Robert | Director | – | Jun 23, 2026 | 1 |
| Link Matthew | Director | – | Jun 23, 2026 | 1 |
| Cilento Richard C. Jr. | Director | – | Jun 23, 2026 | 1 |
| Niklas Victoria Ninon Olivia | Director | – | Jun 23, 2026 | 1 |
| Davis Jason | Chief Financial Officer | 70,000 | May 4, 2026 | 2 |
| O'Heeron Pete | CHIEF EXECUTIVE OFFICER | 5,958,147 | May 4, 2026 | 2 |
| Garcia Ruben A | General Counsel | 180,000 | May 4, 2026 | 3 |
| Coen Stacy Ann | Director | – | Jun 12, 2025 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 (view filing)8:00 AM ET | Mar 4 | 1 day | Khoja HamidChief Scientific Officer | PPurchase | +30.0K | $0.38 | +$11.4K | +96.0%61.3K after | |
| Mar 4, 2026 (view filing)5:50 PM ET | Mar 2-4 | 2 days | O'Heeron PeteCHIEF EXECUTIVE OFFICER | PPurchase | +51.5K | $0.3792 | +$19.5K | +0.9%5.96M after | 3 lots |
| Mar 3, 2026 (view filing)8:00 AM ET | Mar 2 | 1 day | Davis JasonChief Financial Officer | PPurchase | +70.0K | $0.4139 | +$29.0K | New position70.0K after | |
| Mar 2, 2026 (view filing)9:15 AM ET | Feb 27 | 3 days | Garcia Ruben AGeneral Counsel | PPurchase | +40.0K | $0.3264 | +$13.1K | +28.6%180.0K after | |
| Dec 12, 2025 (view filing)7:16 AM ET | Dec 11 | 1 day | Garcia Ruben AGeneral Counsel | PPurchase | +140.0K | $0.34 | +$47.6K | New position140.0K after | |
| May 27, 2025 (view filing) | May 27 | Same day | Khoja HamidChief Scientific Officer | PPurchase | +20.0K | $0.84 | +$16.8K | +177.8%31.3K after | |
| Aug 12, 2024 (view filing) | Aug 12 | Same day | O'Heeron PeteChief Executive Officer | PPurchase | +8.50K | $1.91 | +$16.2K | +0.1%6.06M after | |
| Aug 12, 2024 (view filing) | Aug 12 | Same day | Khoja HamidChief Scientific Officer | PPurchase | +10.0K | $1.90 | +$19.0K | +800.0%11.3K after |